Goserelin: Perbedaan antara revisi
Rescuing 4 sources and tagging 0 as dead.) #IABot (v2.0.9.5 |
+ 4 Kategori; ±Kategori:Peptida→Kategori:Dekapeptida menggunakan HotCat |
||
Baris 67: | Baris 67: | ||
* [http://news.bbc.co.uk/1/hi/health/6320397.stm One man's experience of prostate cancer treatment using goserelin] {{Webarchive|url=https://web.archive.org/web/20090201124046/http://news.bbc.co.uk/1/hi/health/6320397.stm |date=2009-02-01 }} - [[BBC News]] |
* [http://news.bbc.co.uk/1/hi/health/6320397.stm One man's experience of prostate cancer treatment using goserelin] {{Webarchive|url=https://web.archive.org/web/20090201124046/http://news.bbc.co.uk/1/hi/health/6320397.stm |date=2009-02-01 }} - [[BBC News]] |
||
[[Kategori: |
[[Kategori:Dekapeptida]] |
||
[[Kategori:Merek AstraZeneca]] |
|||
[[Kategori:Agonis GnRH]] |
|||
[[Kategori:Terapi hormon feminin]] |
|||
[[Kategori:Obat Esensial Organisasi Kesehatan Dunia]] |
|||
Revisi per 28 Oktober 2023 15.04
![]() | |
---|---|
![]() | |
Nama sistematis (IUPAC) | |
N-(21-((1H-indol-3-yl)methyl)-1,1-diamino-12-(tert-butoxymethyl)-6-(2-(2-carbamoylhydrazinecarbonyl)cyclopentanecarbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-5-yl)-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacos-1-en-24-yl)-5-oxopyrrolidine-2-carboxamide | |
Data klinis | |
Nama dagang | Zoladex, lainnya |
AHFS/Drugs.com | monograph |
MedlinePlus | a601002 |
Kat. kehamilan | D (3.6mg) / X (10.8mg) (Amerika Serikat) |
Status hukum | ℞ Preskripsi saja |
Rute | Implan |
Data farmakokinetik | |
Ikatan protein | 27.3% |
Waktu paruh | 4–5 jam |
Pengenal | |
Nomor CAS | 65807-02-5 ![]() |
Kode ATC | L02AE03 |
PubChem | CID 5311128 |
Ligan IUPHAR | 3879 |
DrugBank | DB00014 |
ChemSpider | 4470656 ![]() |
UNII | 0F65R8P09N ![]() |
KEGG | D04405 ![]() |
ChEBI | CHEBI:5523 ![]() |
ChEMBL | CHEMBL1201247 ![]() |
Sinonim | D-Ser(But)6Azgly10LHRH |
Data kimia | |
Rumus | C59H84N18O14 |
Massa mol. | 1269.410 g/mol |
|
Goserelin (INN, USAN, BAN), atau goserelin asetat, dijual dengan merk dagang Zoladex (oleh AstraZeneca), adalah obat yang digunakan untuk menekan produksi hormon seks (testosterone dan estrogen), khususnya dalam penanganan kanker payudara dan prostat.[1][2]
Goserelin dapat menyebabkan efek samping seperti rasa sakit di tulang, sakit kepala, sakit perut, depresi, kesulitan buang air kecil, berat badan naik, payudara membengkak, kesulitan ereksi, dan berkurangnya nafsu seksual. Pengguna goserelin juga dapat kehilangan ingatan.[3][4]
Penggunaan Zoladex diizinkan di Amerika Serikat pada tahun 1989 untuk menangani kanker prostat.[5]
Referensi
- ^ Dictionary of Organic Compounds. CRC Press. hlm. 3372–. ISBN 978-0-412-54090-5. Diarsipkan dari versi asli tanggal 2023-08-07. Diakses tanggal 2018-05-18.
- ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. hlm. 136–. ISBN 978-94-011-4439-1. Diarsipkan dari versi asli tanggal 2023-08-07. Diakses tanggal 2018-05-18.
- ^ Newton CR, Yuzpe AA, Timmon IS, Slota MD. Memory complaints: a side effect of continued exposure to gonadotropin-releasing hormone agonists (GnRHa). Paper presented at: Conjoint Annual Meetings of the American Fertility Society and the Canadian Fertility and Andrology Society; October 11–14, 1993; Montreal, Canada.
- ^ Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate depot treatment. Fertil Steril. 1993;59(2):448-450.
- ^ "FDA Approval for Zoladex 3.6 mg". Diarsipkan dari versi asli tanggal 2007-03-04. Diakses tanggal 2018-05-18.
Pranala luar
- One man's experience of prostate cancer treatment using goserelin Diarsipkan 2009-02-01 di Wayback Machine. - BBC News